Caris Life Sciences

Caris contributed WES and clinical data to a recent Nature publication on MSK-CHORD, an expansive dataset integrating NLP-derived annotations with clinical and genomic information from 24,950 patients. Our data played a crucial role in validating SETD2 as a biomarker for improved immunotherapy outcomes in lung adenocarcinoma, emphasizing the value of integrating multimodal oncology data. Read more: https://lnkd.in/gCXK828y

Caris Life Sciences is proud to announce that it has published more than 1,000 studies across peer-reviewed manuscripts, posters, and abstracts since 2015, in collaboration with its research partners.    This achievement underscores Caris' unwavering commitment to advancing the field of precision medicine and improving patient outcomes through innovative molecular science and artificial intelligence.   "We are excited to continue pushing the boundaries of precision medicine and contributing valuable insights to the scientific community. Great science takes a team effort. The combination of clinical experts, tumor biologists and data scientists highlights the power of the Caris POA to drive innovation," said Caris President David Spetzler, MS, PhD, MBA.   Learn more: https://lnkd.in/gyAEKhWN

Caris Life Sciences is pleased to announce the appointment of James Hamrick, MD, MPH, as Chairman of the Caris Precision Oncology Alliance™ (Caris POA). Dr. Hamrick will lead the Caris POA, a growing global network of leading cancer centers and research consortia that collaborate to advance precision oncology and biomarker-driven research to improve clinical outcomes for cancer patients. “James’ extensive expertise in oncology and real-world data will propel the mission forward, fostering innovation and collaboration. I look forward to the remarkable advancements we will achieve together in improving patient outcomes and transforming cancer care,” said George Sledge, Jr., MD, EVP and Chief Medical Officer of Caris. Learn more: https://lnkd.in/e_9A_3FA

Caris and collaborators from leading cancer centers, including those within the Caris Precision Oncology Alliance™ (Caris POA), collectively presented studies across a range of breast cancer types, including male breast cancer, at the San Antonio Breast Cancer Symposium (SABCS). Visit Caris at booth 1217 to find out more. ▶ Slide 1: Prognostic implications of oncogenetic pathway alterations in advanced male breast cancer ▪️ In Photo: Dario Trapani Sanchin Kumar Deshmukh Jose P. Leone ▶ Slide 2: Molecular and Immune Landscape of Metaplastic Triple Negative Breast Cancer Compared with Invasive Ductal Triple Negative Breast Cancer ▪️Lead Author and Presenter: Pooja Advani ▶ Slide 3: Molecular landscape of HR+/HER2- male breast cancer (MaBC) compared with female breast cancer (FeBC) ▪️In Photo: Dario Trapani Jose P. Leone ▶ Slide 4: Comprehensive characterization of androgen receptor in male breast cancer ▪️In Photo: Sachin Kumar Deshmukh ▶ Slide 5: Molecular and immunological characterization of HER2-low, HER2 ultra-low, and HER2-null male breast cancer ▪️Presenter: Dario Trapani 

Caris is exhibiting now at #SABCS24! Visit us at booth 1217 to explore the latest trends in precision medicine and learn about our product offerings. Let’s connect, exchange insights, and discuss the future of oncology. We look forward to seeing you. http://ow.ly/TOMR50KB6nW

Why do some #breastcancer patients develop resistance to Trastuzumab Deruxtecan (T-DXd)? Caris analyzed WTS, immunohistochemistry, and real-world clinical data from over 2,000 T-DXd-treated breast cancer samples. This multi-omic approach revealed a clinically relevant mechanism of resistance to T-DXd, which is commonly used in the treatment of metastatic HER2-low and HER2-positive breast cancer. Join Dr. George Sledge, Jr., Chief Medical Officer of Caris Life Sciences, at the SABCS Spotlight Poster presentation to discover how these findings may help oncologists tailor more effective treatment plans for breast cancer patients.

What makes metaplastic triple-negative #breastcancer (M-TNBC) so aggressive? Caris and its collaborators conducted a study using WES and WTS to compare the molecular and immunological characteristics of M-TNBC with those of invasive ductal TNBC, a less aggressive tumor type. The findings from this research will be shared today in a Spotlight Poster presentation during #SABCS24. https://lnkd.in/ga9tAZ8

Are there molecular and immunological differences between HER2-low, HER2-ultra-low and HER2-null/negative #breastcancer in males? A study by Caris and collaborators showed that these historically ‘HER2-negative’ subtypes share genomic features but have different tumor immune microenvironments. Learn more about these findings, which expand our current understanding of the HER2 spectrum in male breast cancer, at our poster. #SABCS24 https://lnkd.in/ga9tAZ8

Do the same mutations affect prognosis differently in male and female #breastcancer? A study of WES/WTS data from >17,700 breast tumors by Caris and collaborators found that select mutations have different effects on breast cancer-related survival in men and women. #SABCS24 https://lnkd.in/ga9tAZ8